Welcome to our dedicated page for Revelation Biosciences SEC filings (Ticker: REVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing the science-heavy disclosures in Revelation Biosciences’ 300-page 10-K can feel like wading through a lab notebook. Clinical trial costs for the Gemini TLR-4 agonist, dilution from new share offerings, and FDA risk factors are buried in dense footnotes. If you have ever searched for “Revelation Biosciences insider trading Form 4 transactions” or wondered how to find the next Gemini milestone in an 8-K, you know the challenge.
Stock Titan solves this complexity. Our platform delivers AI-powered summaries that turn every Revelation Biosciences annual report 10-K simplified into a few digestible paragraphs, flags cash-burn trends in each Revelation Biosciences quarterly earnings report 10-Q filing, and provides Form 4 insider transactions real-time alerts the moment executives act. You’ll also see side-by-side comparisons of trial spending, capital raises, and liquidity ratios—without combing through dozens of exhibits.
Looking for practical answers? Use our search bar to surface:
- Revelation Biosciences 8-K material events explained—read-outs on Gemini-SSI or AKI trial updates.
- Revelation Biosciences proxy statement executive compensation—breakdowns of option grants and performance milestones.
- Revelation Biosciences earnings report filing analysis—AI commentary on quarter-over-quarter R&D variance.
- Understanding Revelation Biosciences SEC documents with AI—step-by-step guides built for biotech investors.
- Revelation Biosciences executive stock transactions Form 4 to gauge insider conviction before pivotal data drops.
All filings are updated from EDGAR in real time, so you never miss a Gemini program headline. Complex biotech disclosures now read like clear, actionable insights.
Revelation Biosciences (REVB) filed a Form S-8 to register 4,647,222 additional shares of common stock for issuance under its 2021 Equity Incentive Plan. The filing incorporates prior S-8 registrations by reference under General Instruction E. This expands the pool of shares available for equity awards to employees, directors, and consultants.
Revelation Biosciences (REVB) called a Special Meeting on December 3, 2025 to seek stockholder approval to reserve and issue common shares upon exercise of Class I Warrants in amounts that may exceed Nasdaq’s 20% Exchange Cap under Rule 5635(d). A second proposal would allow adjournment if more votes are needed.
The request follows a September 2025 warrant inducement in which holders exercised 13,065,000 Class H Warrants into 4,355,000 shares at $2.20 per share, and received 13,065,000 Class I Warrants (exercisable for five years from stockholder approval at $2.20). The Company reported gross proceeds of approximately $9.6 million from this transaction.
Key mechanics: record date is October 29, 2025 with 5,924,137 shares outstanding; quorum is 1,974,713 shares. Warrant holders will vote their shares in the same proportion as disinterested stockholders. If Proposal 1 is not approved, the Company cannot issue or agree to issue common stock or equivalents and must hold meetings every 60 days; prior adjournments added about $50,000 in costs.
Revelation Biosciences, Inc. furnished an 8‑K announcing it issued a press release with financial results for the three and nine months ended September 30, 2025.
The release is included as Exhibit 99.1 under Item 2.02 and will not be treated as “filed” or incorporated by reference unless expressly stated.
Revelation Biosciences (REVB) reported Q3 2025 results, highlighting higher liquidity alongside a continued net loss and a going concern warning. Cash and cash equivalents were $12.7 million as of September 30, 2025, up from $6.5 million at year-end, supported by financing activity.
For the quarter, the company recorded a net loss of $1.91 million on operating expenses of $1.94 million (R&D $0.92 million; G&A $1.02 million). For the nine months, the net loss was $6.40 million. Stockholders’ equity rose to $11.0 million. The share count increased following two reverse stock splits in 2025 and subsequent warrant-related issuances.
Management disclosed that current cash is not expected to sustain operations within one year after issuance of the financial statements, indicating substantial doubt about continuing as a going concern. Financing events included the May 2025 public offering with net proceeds of $3.4 million and a September 2025 Class H warrant inducement generating net proceeds of $8.7 million. As of November 4, 2025, 5,924,137 shares were outstanding.
Revelation Biosciences (REVB) director reported an equity grant. On 10/29/2025, the insider acquired 15,625 shares of common stock (Code A) at $1.28 per share under the 2021 Equity Incentive Plan. The award vests 100% on January 28, 2026. Following the grant, the reporting person beneficially owned 15,686 shares, held directly.
Revelation Biosciences (REVB) reported an insider equity grant. On 10/29/2025, CEO and Director James Rolke acquired 390,614 shares of common stock as a restricted stock grant under the 2021 Equity Incentive Plan.
The award vests quarterly over one year from the grant date. Following the transaction, Rolke beneficially owned 400,660 shares, held directly.
Revelation Biosciences (REVB) reported an insider equity award. A company director acquired 15,625 shares of Common Stock on 10/29/2025, reported at a $1.28 price per share, as a restricted stock grant under the 2021 Equity Incentive Plan.
The grant vests 100% on January 28, 2026. Following the transaction, the reporting person beneficially owned 15,688 shares, held directly.
Revelation Biosciences (REVB) reported an insider equity award for its Chief Financial Officer, Chester S. Zygmont III. On 10/29/2025, the CFO acquired 390,614 shares of common stock as a restricted stock grant under the 2021 Equity Incentive Plan at a stated price of
Following the reported transaction, the filing lists 395,645 shares of common stock indirectly held by The Zygmont Family Trust, and additional small indirect holdings of 5,026 shares by the trust and 5 shares by Czeslaw Capital Fund, LLC. The filing indicates the use of indirect ownership structures (trust and LLC) and confirms the CFO’s status as an officer.
Revelation Biosciences (REVB) reported an insider equity award. Director Jess Roper acquired 15,625 shares of Common Stock on 10/29/2025 at $1.28 per share, coded as an acquisition. Following the transaction, the director beneficially owned 15,686 shares, held directly.
The shares were a Restricted Stock Grant under the 2021 Equity Incentive Plan and vest 100% on January 28, 2026.
Revelation Biosciences (REVB)
The company set a new record date of October 29, 2025 for a new Special Meeting to be held on December 3, 2025. The disclosure is furnished under Item 7.01 (Regulation FD), and a related press release is included as Exhibit 99.1.
FAQ
What is the current stock price of Revelation Biosciences (REVB)?
What is the market cap of Revelation Biosciences (REVB)?
